Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Appl...
Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
Cabergoline is a dopamine agonist that has been used as the first-line treatment option for prolactin-secreting pituitary adenomas for several decades. It not only suppresses hormone production from these prolactinomas, but also causes tumour shrinkage. Recent studies revealed some novel mechanisms by which cabergoline suppresses tumour cell prolif...
Alternative Titles
Full title
Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_31597135
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_31597135
Other Identifiers
ISSN
0028-3835
E-ISSN
1423-0194
DOI
10.1159/000504000
